# Tetramer Research & Development Contract (Influenza)

> **NIH NIH N01** · EMORY UNIVERSITY · 2022 · $200,000

## Abstract

The NIH Tetramer Core Facility provides valuable resources to the research community that enable cutting edge research in basic immunology and a wide variety of infectious disease areas (including the influenza virus) via production and distribution of class I, class II and CD1 reagents. The reagents are being applied to studies of antigen processing and presentation, T cell activation, T cell responses against microbial pathogens or tumors, and T cell-mediated exacerbation or amelioration of immune-mediated diseases. This contract conducts research and development that would enhance the quality, functionality (e.g., sensitivity), and breadth of available tetramer reagents and decrease production time.

## Key facts

- **NIH application ID:** 10678192
- **Project number:** 75N93020D00005-0-759302200001-3
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** JOHN ALTMAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $200,000
- **Award type:** —
- **Project period:** 2020-03-21 → 2027-03-20

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10678192

## Citation

> US National Institutes of Health, RePORTER application 10678192, Tetramer Research & Development Contract (Influenza) (75N93020D00005-0-759302200001-3). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10678192. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*